These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27680310)

  • 1. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease.
    Griffett K; Burris TP
    Biochem Biophys Res Commun; 2016 Oct; 479(3):424-428. PubMed ID: 27680310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursolic Acid, a Novel Liver X Receptor α (LXRα) Antagonist Inhibiting Ligand-Induced Nonalcoholic Fatty Liver and Drug-Induced Lipogenesis.
    Lin YN; Wang CCN; Chang HY; Chu FY; Hsu YA; Cheng WK; Ma WC; Chen CJ; Wan L; Lim YP
    J Agric Food Chem; 2018 Nov; 66(44):11647-11662. PubMed ID: 30359008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A liver-selective LXR inverse agonist that suppresses hepatic steatosis.
    Griffett K; Solt LA; El-Gendy Bel-D; Kamenecka TM; Burris TP
    ACS Chem Biol; 2013 Mar; 8(3):559-67. PubMed ID: 23237488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor.
    Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW
    J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma.
    Na TY; Shin YK; Roh KJ; Kang SA; Hong I; Oh SJ; Seong JK; Park CK; Choi YL; Lee MO
    Hepatology; 2009 Apr; 49(4):1122-31. PubMed ID: 19105208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteolin improves non-alcoholic fatty liver disease in db/db mice by inhibition of liver X receptor activation to down-regulate expression of sterol regulatory element binding protein 1c.
    Yin Y; Gao L; Lin H; Wu Y; Han X; Zhu Y; Li J
    Biochem Biophys Res Commun; 2017 Jan; 482(4):720-726. PubMed ID: 27888103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hexane Fraction of cyperus rotundus Prevents Non-Alcoholic Fatty Liver Disease Through the Inhibition of Liver X Receptor α-Mediated Activation of Sterol Regulatory Element Binding Protein-1c.
    Oh GS; Yoon J; Lee GG; Kwak JH; Kim SW
    Am J Chin Med; 2015; 43(3):477-94. PubMed ID: 25967664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice.
    Jung UJ; Millman PN; Tall AR; Deckelbaum RJ
    Biochim Biophys Acta; 2011 Sep; 1811(9):491-7. PubMed ID: 21704188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC5 Inhibits Hepatic Lipogenic Genes Expression by Attenuating the Transcriptional Activity of Liver X Receptor.
    Jia HY; Li QZ; Lv LF
    Cell Physiol Biochem; 2016; 39(4):1561-7. PubMed ID: 27614433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice.
    Sheng X; Wang M; Lu M; Xi B; Sheng H; Zang YQ
    Am J Physiol Endocrinol Metab; 2011 May; 300(5):E886-93. PubMed ID: 21364120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
    Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
    J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
    Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clusterin decreases hepatic SREBP-1c expression and lipid accumulation.
    Seo HY; Kim MK; Jung YA; Jang BK; Yoo EK; Park KG; Lee IK
    Endocrinology; 2013 May; 154(5):1722-30. PubMed ID: 23515283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver.
    Sim WC; Park S; Lee KY; Je YT; Yin HQ; Choi YJ; Sung SH; Park SJ; Park HJ; Shin KJ; Lee BH
    Biochem Pharmacol; 2014 Aug; 90(4):414-24. PubMed ID: 24955981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osthol ameliorates fat milk-induced fatty liver in mice by regulation of hepatic sterol regulatory element-binding protein-1c/2-mediated target gene expression.
    Du R; Xue J; Wang HB; Zhang Y; Xie ML
    Eur J Pharmacol; 2011 Sep; 666(1-3):183-8. PubMed ID: 21620823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.
    Zhou J; Febbraio M; Wada T; Zhai Y; Kuruba R; He J; Lee JH; Khadem S; Ren S; Li S; Silverstein RL; Xie W
    Gastroenterology; 2008 Feb; 134(2):556-67. PubMed ID: 18242221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
    Hwahng SH; Ki SH; Bae EJ; Kim HE; Kim SG
    Hepatology; 2009 Jun; 49(6):1913-25. PubMed ID: 19378344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siphonaxanthin, a Carotenoid From Green Algae, Inhibits Lipogenesis in Hepatocytes via the Suppression of Liver X Receptor α Activity.
    Zheng J; Li Z; Manabe Y; Kim M; Goto T; Kawada T; Sugawara T
    Lipids; 2018 Jan; 53(1):41-52. PubMed ID: 29446839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbenoxolone prevents the development of fatty liver in C57BL/6-Lep ob/ob mice via the inhibition of sterol regulatory element binding protein-1c activity and apoptosis.
    Rhee SD; Kim CH; Park JS; Jung WH; Park SB; Kim HY; Bae GH; Kim TJ; Kim KY
    Eur J Pharmacol; 2012 Sep; 691(1-3):9-18. PubMed ID: 22742899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.